Submitted by Anonymous (not verified) on 5 October 2023 - 13:43
Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Myelodysplastic Syndromes;Leukemia, Myelomonocytic, Chronic;Leukemia, Myeloid, Acute, Date of authorisation: 27/03/2020, Revision: 7, Status: Authorised
Source: